
Pfizer Inc
NYSE:PFE

Intrinsic Value
The intrinsic value of one
PFE
stock under the Base Case scenario is
53.17
USD.
Compared to the current market price of 43.94 USD,
Pfizer Inc
is
Undervalued by 17%.
The Intrinsic Value is calculated as the average of the two valuation methods:

Fundamental Analysis
PFE Profitability Score
Profitability Due Diligence
Pfizer Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
Score
Pfizer Inc's profitability score is 71/100. The higher the profitability score, the more profitable the company is.
PFE Solvency Score
Solvency Due Diligence
Pfizer Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Pfizer Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Pfizer Inc
PFE Capital Structure
Pfizer Inc
Market Capitalization | 247B USD | |
Total Debt | 34.1B USD | |
Minority Interest | 259M USD | |
Preferred Equity | 0 USD | |
Cash and Equivalents | 1.3B USD | |
Short-Term Investments | 34.8B USD | |
Enterprise Value | 245B USD |
Wall St
Price Targets
PFE Price Targets Summary
Pfizer Inc
According to Wall Street analysts, the average 1-year price target for
PFE
is 56.6 USD
with a low forecast of 44.44 USD and a high forecast of 78.75 USD.
Competitive Landscape
PFE Competitors
Pfizer Inc
PFE Suppliers & Customers
Pfizer Inc
Pfizer Inc has 167 key suppliers from 18 countries and 19 industries. The majority of these suppliers are located in the United States of America, with the largest number of suppliers in the Biotechnology industry.
Pfizer Inc has 77 key customers from 11 countries and 6 industries. The majority of these customers are located in the United States of America, with the largest number of customers in the Biotechnology industry.
Ownership
PFE Insider Trading
Buy and sell transactions by insiders
During the last 12 months Pfizer Inc insiders have not bought any shares, and sold 7.2M USD worth of shares. The last transaction was made on Feb 6, 2023 by Damico Jennifer B. (SVP & Controller), who sold 228k USD worth of PFE shares.
Shareholder Return
PFE Price
Pfizer Inc
Average Annual Return | 20.73% |
Standard Deviation of Annual Returns | 29.38% |
Max Drawdown | -35% |
Market Capitalization | 247B USD |
Shares Outstanding | 5 613 310 000 |
Percentage of Shares Shorted | 1.25% |
Company Profile

Country
Industry
Market Cap
Dividend Yield
Description
Pfizer Inc. is a research-based global biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 79,000 full-time employees. The firm is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines. The firm offers therapeutic candidates in gastroenterology, dermatology, and cardiology, including etrasimod, an oral, selective sphingosine 1-phosphate (S1P) receptor modulator in development for a range of immuno-inflammatory diseases, including ulcerative colitis, Crohn’s Disease, atopic dermatitis, eosinophilic esophagitis, and alopecia areata. The firm works across markets to develop wellness, prevention, treatments and cures. The company collaborates with healthcare providers, governments and local communities to support and provide access to healthcare. The firm's medicines and vaccines provide value for healthcare providers and patients, through treatment of diseases, improvements in health, wellness.
Contact
IPO
Employees
Officers
The intrinsic value of one
PFE
stock under the Base Case scenario is
53.17
USD.
Compared to the current market price of 43.94 USD, Pfizer Inc is Undervalued by 17%.